AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global impression of
AbCellera's new medicine worked really well in testing—it helped people with hot flashes feel much better after just one dose. When a company's medicine does what doctors hoped in tests, it's a sign the company might be on the right track, so it's worth paying attention to what happens next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.